Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 86Bevacizumab 66Capecitabine 65Fluorouracil 48tislelizumab 41Gemcitabine 40Drug Therapy 39Leucovorin 38sintilimab 35Irinotecan 34lenvatinib 27Cisplatin 27HMPL-013 25S 1 (combination) 23camrelizumab 22Immune Checkpoint Inhibitors 21irinotecan sucrosofate 20apatinib 20Surgical Procedures, Operative 20Radiotherapy 20Injections 20130-nm albumin-bound paclitaxel 20toripalimab 19Paclitaxel 18Folfox protocol 17pembrolizumab 15Immunotherapy 15Cetuximab 15Specimen Handling 14regorafenib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Olanzapine × Gastrointestinal × Clear all
NCT07581405 2026-05-12

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

University of Illinois at Chicago

Phase 2 Not yet recruiting
26 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡